Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 Sep;101(1):81–88. doi: 10.1111/j.1476-5381.1990.tb12093.x

Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat.

S A Douglas 1, C R Hiley 1
PMCID: PMC1917627  PMID: 2282471

Abstract

1. The vasoconstrictor activities of endothelin-2, endothelin-3, sarafotoxin S6b, human proendothelin1-38 and mouse vasoactive intestinal contractor (VIC) were studied in the isolated Krebs-Henseleit perfused mesenteric arterial bed of the rat in the presence and absence of the endothelium. The vasoconstrictor properties of endothelin-1 were studied in control preparations and in preparations treated with methylene blue or N omega-nitro-L-arginine methyl ester (NAME). Finally, the direct vasodilator properties of endothelin-2, endothelin-3 and sarafotoxin S6b were studied in preparations preconstricted with methoxamine. 2. In the presence of an intact endothelium, all of the peptides caused dose-dependent increases in perfusion pressure and sarafotoxin S6b was a full agonist relative to the other peptides studied (maximum increase in perfusion pressure, Rmax = 106 +/- 11 mmHg). Endothelin-1, endothelin-2 and VIC were more potent vasoconstrictors (ED50 93.0 +/- 40.0, 90.8 +/- 20.5 and 106 +/- 63 pmol, respectively) than endothelin-3 and sarafotoxin S6b, which were found to be equipotent (ED50 values 411 +/- 195 and 345 +/- 86 pmol, respectively). A full dose-response relationship could not be constructed for proendothelin, but the highest dose used (4 nmol) increased the perfusion pressure by 15.4 +/- 1.6 mmHg. 3. Destruction of the endothelium with the zwitterionic detergent 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulphonate (CHAPS) significantly enhanced the pressor activity of all 5 peptides. The Rmax for sarafotoxin S6b was not significantly altered by removal of the endothelium but its potency was significantly increased (ED50 = 115 +/- 15 pmol).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aceves J., Mariscal S., Morrison K. E., Young J. M. The binding of doxepin to histamine H1-receptors in guinea-pig and rat brain. Br J Pharmacol. 1985 Feb;84(2):417–424. doi: 10.1111/j.1476-5381.1985.tb12925.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ambar I., Kloog Y., Schvartz I., Hazum E., Sokolovsky M. Competitive interaction between endothelin and sarafotoxin: Binding and phosphoinositides hydrolysis in rat atria and brain. Biochem Biophys Res Commun. 1989 Jan 16;158(1):195–201. doi: 10.1016/s0006-291x(89)80197-4. [DOI] [PubMed] [Google Scholar]
  3. Collier J., Vallance P. Second messenger role for NO widens to nervous and immune systems. Trends Pharmacol Sci. 1989 Nov;10(11):427–431. doi: 10.1016/s0165-6147(89)80001-x. [DOI] [PubMed] [Google Scholar]
  4. Förstermann U., Neufang B. The endothelium-dependent relaxation of rabbit aorta: effects of antioxidants and hydroxylated eicosatetraenoic acids. Br J Pharmacol. 1984 Aug;82(4):765–767. doi: 10.1111/j.1476-5381.1984.tb16472.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gu X. H., Casley D., Nayler W. Specific high-affinity binding sites for 125I-labelled porcine endothelin in rat cardiac membranes. Eur J Pharmacol. 1989 Aug 22;167(2):281–290. doi: 10.1016/0014-2999(89)90589-x. [DOI] [PubMed] [Google Scholar]
  6. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863–2867. doi: 10.1073/pnas.86.8.2863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Itoh Y., Yanagisawa M., Ohkubo S., Kimura C., Kosaka T., Inoue A., Ishida N., Mitsui Y., Onda H., Fujino M. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. FEBS Lett. 1988 Apr 25;231(2):440–444. doi: 10.1016/0014-5793(88)80867-6. [DOI] [PubMed] [Google Scholar]
  8. Kashiwabara T., Inagaki Y., Ohta H., Iwamatsu A., Nomizu M., Morita A., Nishikori K. Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett. 1989 Apr 10;247(1):73–76. doi: 10.1016/0014-5793(89)81243-8. [DOI] [PubMed] [Google Scholar]
  9. Kloog Y., Ambar I., Sokolovsky M., Kochva E., Wollberg Z., Bdolah A. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science. 1988 Oct 14;242(4876):268–270. doi: 10.1126/science.2845579. [DOI] [PubMed] [Google Scholar]
  10. Kloog Y., Bousso-Mittler D., Bdolah A., Sokolovsky M. Three apparent receptor subtypes for the endothelin/sarafotoxin family. FEBS Lett. 1989 Aug 14;253(1-2):199–202. doi: 10.1016/0014-5793(89)80958-5. [DOI] [PubMed] [Google Scholar]
  11. MCGREGOR D. D. THE EFFECT OF SYMPATHETIC NERVE STIMULATION OF VASOCONSTRICTOR RESPONSES IN PERFUSED MESENTERIC BLOOD VESSELS OF THE RAT. J Physiol. 1965 Mar;177:21–30. doi: 10.1113/jphysiol.1965.sp007572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maggi C. A., Giuliani S., Patacchini R., Santicioli P., Rovero P., Giachetti A., Meli A. The C-terminal hexapeptide, endothelin-(16-21), discriminates between different endothelin receptors. Eur J Pharmacol. 1989 Jul 4;166(1):121–122. doi: 10.1016/0014-2999(89)90693-6. [DOI] [PubMed] [Google Scholar]
  13. Martin W., Villani G. M., Jothianandan D., Furchgott R. F. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther. 1985 Mar;232(3):708–716. [PubMed] [Google Scholar]
  14. Moore P. K., al-Swayeh O. A., Chong N. W., Evans R. A., Gibson A. L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol. 1990 Feb;99(2):408–412. doi: 10.1111/j.1476-5381.1990.tb14717.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pohl U., Busse R. Differential vascular sensitivity to luminally and adventitially applied endothelin-1. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S188–S190. doi: 10.1097/00005344-198900135-00052. [DOI] [PubMed] [Google Scholar]
  16. Randall M. D., Douglas S. A., Hiley C. R. Vascular activities of endothelin-1 and some alanyl substituted analogues in resistance beds of the rat. Br J Pharmacol. 1989 Oct;98(2):685–699. doi: 10.1111/j.1476-5381.1989.tb12644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Saida K., Mitsui Y., Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J Biol Chem. 1989 Sep 5;264(25):14613–14616. [PubMed] [Google Scholar]
  18. Warner T. D., de Nucci G., Vane J. R. Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol. 1989 Jan 17;159(3):325–326. doi: 10.1016/0014-2999(89)90167-2. [DOI] [PubMed] [Google Scholar]
  19. Watanabe H., Miyazaki H., Kondoh M., Masuda Y., Kimura S., Yanagisawa M., Masaki T., Murakami K. Two distinct types of endothelin receptors are present on chick cardiac membranes. Biochem Biophys Res Commun. 1989 Jun 30;161(3):1252–1259. doi: 10.1016/0006-291x(89)91377-6. [DOI] [PubMed] [Google Scholar]
  20. Yanagisawa M., Inoue A., Ishikawa T., Kasuya Y., Kimura S., Kumagaye S., Nakajima K., Watanabe T. X., Sakakibara S., Goto K. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6964–6967. doi: 10.1073/pnas.85.18.6964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES